Back to All

Proficiency assessment of HER2 scoring in breast cancer

16 January, 2023

Proficiency assessment of HER-2 scoring in breast cancer 

Over the last 20 years, pathological assessment of human epidermal growth factor receptor 2 (HER2) status has been essential in the selection of patients with breast cancer eligible for HER2-targeted therapies.43 To date, pathologists have focused on the identification of HER2-positive tumors defined as exhibiting either immunohistochemical (IHC) receptor protein overexpression (IHC score 3+ or IHC 2+ borderline score with HER2 gene amplification) based on the ASCO or College of American Pathologists (CAP) criteria.44 However, more recently, a new type of HER2-targeted therapy has been developed showing benefit in HER2-low breast carcinomas, with low level HER2 expression without HER2 gene amplification.45,46 Therefore, the question arises as to whether the current practice of HER2 testing allows the precise distinction of HER2-low categories that have to date been classified as HER2 negative.  

In a global real-world laboratory study sponsored by Diaceutics, HER2 scoring proficiency was evaluated across 75 pathologists to determine the current ability to distinguish low levels of HER2 expression and identify challenges in HER2-low scoring in breast cancer. Digitized images of tissue sections were selected to cover a range of IHC scores with a focus on samples at the border between IHC 1+ and IHC 0 according to ASCO/CAP criteria. As part of the methodology, pathologists were also required to provide their own experience in HER2 staining and scoring methods through the Diaceutics DXRX platform.  

The study found high levels of agreement among pathologists in the identification of the existing ASCO/CAP HER2 categories of negative versus positive, independent of training. However, after introducing the HER2-low category, a decrease in agreement rates was observed, with training only having a minor overall effect. This demonstrated a need for improved guidance on the classification of HER2-low cases. Leading authors of this article are to propose an improved HER2 IHC staining classification system with greater focus on these case types. 

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny